Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Pulmonology
•
Asthma
Would you consider switching to benralizumab for patients with EGPA experiencing severe pulmonary symptoms despite being on mepolizumab?
Do you consider benralizumab for patients with EGPA with severe pulmonary symptoms on mepolizumab?
Related Questions
When would you recommend prescribing an asthmatic patient budesonide/salbutamol rather than budesonide/formoterol?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
How do you manage pleuroparenchymal fibroelastosis in a patient with seronegative RA that is progressing on Rituxan and DMARD therapy?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
What is your approach to management of pulmonary fibrosis in patients with a history of microscopic polyangiitis who do not have other active organ involvement?
Do you start immunosuppression for enlarging pulmonary nodules without symptoms, impaired pulmonary function, or extra-pulmonary disease in a patient with sarcoidosis?
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
How do you approach management of osteoporosis in patients post lung transplant?
How do you factor smoking history into biologic selection for asthma since the clinical trials generally excluded these patients?
Have you observed adverse mental health side effects in patients who start montelukast?